Immunogenicity of a 26-valent group A streptococcal vaccine.
about
Multilocus sequence typing of Streptococcus pyogenes representing most known emm types and distinctions among subpopulation genetic structuresAlphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challengeAccelerating the development of a group A Streptococcus vaccine: an urgent public health needCorrelates of Protection for M Protein-Based Vaccines against Group A StreptococcusAnti-Group A Streptococcal Vaccine Epitope: STRUCTURE, STABILITY, AND ITS ABILITY TO INTERACT WITH HLA CLASS II MOLECULESEpidemiology of Invasive Group A Streptococcal Disease in Alaska, 2001 to 2013.The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease.Relationships between emm and multilocus sequence types within a global collection of Streptococcus pyogenes.National Department of Defense surveillance data for antibiotic resistance and emm gene types of clinical group A streptococcal isolates from eight basic training military sitesBactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.Identification and molecular characterisation of a fibrinogen binding protein from Streptococcus iniae.Streptococcus iniae M-like protein contributes to virulence in fish and is a target for live attenuated vaccine developmentComparative analysis of emm type pattern of Group A Streptococcus throat and skin isolates from India and their association with closely related SIC, a streptococcal virulence factorGroup A streptococcal genotypes from throat and skin isolates in the United Arab EmiratesSurface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.Factors associated with Group A Streptococcus emm type diversification in a large urban setting in Brazil: a cross-sectional study.Identity and prevalence of multilocus sequence typing-defined clones of group A streptococci within a hospital settingHigher rates of streptococcal colonization among children in the Pacific Rim Region correlates with higher rates of group A streptococcal disease and sequelaeThe NH(2)-terminal region of Streptococcus pyogenes M5 protein confers protection against degradation by proteases and enhances mucosal colonization of mice.Six-month multicenter study on invasive infections due to Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis in Argentina.Invasive group A streptococcal infection in older adults in long-term care facilities and the community, United States, 1998-2003Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypesProtective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.Streptococcal emm types in Hawaii: a region with high incidence of acute rheumatic fever.M protein gene (emm type) analysis of group A beta-hemolytic streptococci from Ethiopia reveals unique patterns.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationshipActive and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.Molecular epidemiologic comparison of 2 unusual clusters of group a streptococcal necrotizing fasciitis in Hawaii.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011.Group A streptococcus expresses a trio of surface proteins containing protective epitopes.Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections.Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece.Genes, autoimmunity and pathogenesis of rheumatic heart disease.Evaluation of emm gene types, toxin gene profiles and clonal relatedness of group A streptococciNew 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococciInvasive group A streptococcal infections, clinical manifestations and their predictors, Montreal, 1995-2001.Group A Streptococcus emm gene types in pharyngeal isolates, Ontario, Canada, 2002-2010.
P2860
Q24564671-C8727D7A-7615-446F-AF92-CE6687C49481Q24657762-2C6DBD6E-FD9F-4785-B067-9B99917B9853Q26739210-C9C9DBAF-C3CC-469E-839F-6FA6714A4976Q27009175-A01C2DBD-AA49-4D92-8B76-738BF582A734Q27666345-F75157DD-10F3-43A6-823F-CC90B3276933Q30202103-28887B2B-1765-43F4-AC9A-6B21E659E640Q30432965-748D8F93-5A48-4436-976D-78DBB3579226Q30481807-EE94CE6D-C87B-4974-BE3D-DF8F26CCBBC3Q30881760-80B66074-FC8C-43B8-821B-B63B7AE83C33Q33253260-D6AEC196-B1FE-4395-938D-F05ECAF1EB25Q33330200-F8D78AF5-27C9-4A77-BDDF-9BBD1A83BD34Q33355994-98BA65C3-AF7D-41C4-B8F8-A6B1D1E2BD2DQ33369963-0D18F7F5-7D36-4B8E-9DCD-9EE99EB6FC16Q33549923-F248A5A0-A9E5-4D4F-9DF3-85E2910C6D2BQ33719415-65CB429A-0D94-4B5B-BE76-0405093ACD23Q33744547-320A547A-579A-4ECB-9DC9-58B24EBAC9D3Q33753390-24D09556-3AC9-46F2-B9F4-D0BE2E01F059Q33794061-0E6DAFB8-0154-47D4-A3DA-E83904A0B27EQ33804050-59BB88AB-A8C1-4E6B-97C5-D0DA25E71194Q33824679-FE4CE78A-FE29-4599-8D2B-EA1ACE17A073Q33877781-F9B74BFF-4EF4-4BF4-810C-08E679258B55Q33910815-878D80BC-32A8-42FA-A86A-36FB51968810Q34005434-83480869-194A-47BE-8AB8-4F652B34BFE7Q34036156-0EFAE6BE-DE8E-485B-AAFE-AB2C941696DCQ34042270-494B6884-C150-4F1C-AFC9-421F44AA4AE2Q34112608-00002CC5-724C-4E5C-A384-513531CC589DQ34131142-FE6D62BA-925E-404C-A272-EEE266B133C2Q34194488-4B66D2CB-04C8-4029-8ABF-56FF42BC15AAQ34345145-0830E1F3-F270-4CF5-9ACA-4FF2DFB91F42Q34413457-6B958360-B607-4F3B-8C0A-B5C022E957BEQ34511201-DBC03FA0-9486-44F0-90DF-A66D94F5716AQ34701389-B3C2EFCD-AF18-435D-B18E-7EC40CE66E57Q34885060-218BEDE4-9201-4BF1-934F-35FD57073ECDQ34934867-D4C75F17-8B45-4130-ADD6-019BD78828C0Q34971503-5932114F-4A86-4974-809F-18D7CDE53FA4Q35015039-666F93A6-E098-480C-BDFB-BA09352B95A0Q35099922-5467E39E-CEBC-4F80-96C5-5FFD30B533DBQ35376757-4E6E40CE-5142-4DE1-B4B3-9B80653BC59DQ35804371-C5F91FF5-9075-4422-8F22-5040CE88CE6EQ35847191-F1258FE3-886E-40BD-9F8B-44B632BF70DB
P2860
Immunogenicity of a 26-valent group A streptococcal vaccine.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immunogenicity of a 26-valent group A streptococcal vaccine.
@ast
Immunogenicity of a 26-valent group A streptococcal vaccine.
@en
Immunogenicity of a 26-valent group A streptococcal vaccine.
@nl
type
label
Immunogenicity of a 26-valent group A streptococcal vaccine.
@ast
Immunogenicity of a 26-valent group A streptococcal vaccine.
@en
Immunogenicity of a 26-valent group A streptococcal vaccine.
@nl
prefLabel
Immunogenicity of a 26-valent group A streptococcal vaccine.
@ast
Immunogenicity of a 26-valent group A streptococcal vaccine.
@en
Immunogenicity of a 26-valent group A streptococcal vaccine.
@nl
P2093
P2860
P1476
Immunogenicity of a 26-valent group A streptococcal vaccine
@en
P2093
Bernard Beall
Mark A Reddish
Michael A Walls
Steven D Stroop
P2860
P304
P356
10.1128/IAI.70.4.2171-2177.2002
P407
P50
P577
2002-04-01T00:00:00Z